Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study

Ítems similars

• Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy
  per: Boccia, Ralph V, et al.
  Publicat: (2012)
• Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
  per: Boccia, Ralph, et al.
  Publicat: (2013)
• Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial
  per: Raftopoulos, Harry, et al.
  Publicat: (2014)
• Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review
  per: Tuca, Albert
  Publicat: (2009)
• Clinician preference and comparison of the efficacy of ondansetron, granisetron, and palonosetron in preventing chemotherapy-induced nausea and vomiting among children receiving moderate or highly emetogenic chemotherapy
  per: Rohan Bansal, et al.
  Publicat: (2023-09-01)